Video

Dr. Hubbard on the Barriers of Widely Implementing ctDNA ​Testing in CRC

Joleen M. Hubbard, MD, discusses the barriers of implementing circulating tumor DNA into widespread clinical practice in colorectal cancer.

Joleen M. Hubbard, MD, associate professor of oncology, consultant, practice chair, and vice chair, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the barriers of implementing circulating tumor DNA (ctDNA) into widespread clinical practice in colorectal cancer (CRC).

The field of CRC is developing a greater understanding of how to use technology and ensure technology is benefiting patients in terms of cost-benefit ratio, Hubbard says. Moreover, ctDNA testing is not free and is typically paid for by the health care system, Hubbard adds. Although the technology is welcome in CRC, it is important to consider whether it is helping patients, Hubbard explains.

Ultimately, whether the ability to act upon the results obtained from ctDNA testing outweigh the resources needed to conduct testing remains an unanswered question, Hubbard explains. As such, more data are needed to determine the clinical benefit of this technology before it can be widely implemented in CRC, Hubbard concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
COOMBS
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Montero, MD, MBA, CPHQ
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.
Melanie A. Sheen, MD
Raajit Rampal, MD, director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center